Nuvalent (NASDAQ:NUVL) Sees Strong Trading Volume – Here’s Why

Nuvalent, Inc. (NASDAQ:NUVL) saw strong trading volume on Thursday . 1,265,389 shares changed hands during trading, a decline of 2% from the previous session’s volume of 1,285,246 shares.The stock last traded at $123.4750 and had previously closed at $123.36.

Analysts Set New Price Targets

A number of analysts have recently weighed in on NUVL shares. Lifesci Capital downgraded shares of Nuvalent from an “outperform” rating to a “hold” rating and set a $124.00 price target for the company. in a research report on Tuesday, June 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Nuvalent in a research report on Tuesday, April 21st. HC Wainwright downgraded shares of Nuvalent from a “buy” rating to a “neutral” rating and set a $124.00 price target for the company. in a research report on Tuesday, June 9th. Cantor Fitzgerald downgraded shares of Nuvalent from an “overweight” rating to a “neutral” rating in a research report on Tuesday, June 9th. Finally, Stifel Nicolaus set a $124.00 price target on shares of Nuvalent in a research report on Tuesday, June 9th. Five analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $131.15.

Nuvalent Price Performance

The firm has a market cap of $9.75 billion, a price-to-earnings ratio of -20.36 and a beta of 1.15. The business’s 50-day moving average price is $105.32 and its two-hundred day moving average price is $103.71.

Nuvalent (NASDAQ:NUVL) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.04). During the same period last year, the business earned ($1.18) EPS. Equities analysts predict that Nuvalent, Inc. will post -5.74 earnings per share for the current fiscal year.

Insider Buying and Selling at Nuvalent

In other Nuvalent news, insider Henry E. Pelish sold 3,093 shares of Nuvalent stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $104.48, for a total value of $323,156.64. Following the completion of the transaction, the insider owned 65,604 shares of the company’s stock, valued at $6,854,305.92. The trade was a 4.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Deborah Ann Miller sold 5,500 shares of Nuvalent stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $107.84, for a total transaction of $593,120.00. Following the completion of the transaction, the insider directly owned 59,634 shares of the company’s stock, valued at approximately $6,430,930.56. This represents a 8.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 126,953 shares of company stock worth $12,612,264. Company insiders own 5.02% of the company’s stock.

Hedge Funds Weigh In On Nuvalent

A number of hedge funds have recently added to or reduced their stakes in NUVL. GAMMA Investing LLC boosted its holdings in Nuvalent by 47.6% in the fourth quarter. GAMMA Investing LLC now owns 335 shares of the company’s stock worth $34,000 after purchasing an additional 108 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in Nuvalent by 141.3% in the first quarter. EverSource Wealth Advisors LLC now owns 333 shares of the company’s stock worth $34,000 after purchasing an additional 195 shares during the period. Aster Capital Management DIFC Ltd acquired a new position in Nuvalent in the third quarter worth $38,000. NBC Securities Inc. acquired a new position in Nuvalent in the fourth quarter worth $125,000. Finally, KBC Group NV boosted its holdings in Nuvalent by 24.1% in the fourth quarter. KBC Group NV now owns 1,527 shares of the company’s stock worth $154,000 after purchasing an additional 297 shares during the period. Institutional investors and hedge funds own 97.26% of the company’s stock.

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.